PubMed Health⌕ Search

Biomedical subjects

L Telegdy

Publications and source records attributed to L Telegdy.

At least 37 records · Page 2Linked to original sources
PubMed1993

[Isoprinosine therapy in chronic hepatitis C (multicenter placebo-controlled double-blind prospective study)].

A placebo controlled clinical trial. Thirty two patients with chronic C hepatitis have been enrolled in a double blinded study to assess the therapeutic effect on an orally given antiviral-immunomodulatory drug, Isoprinosine. Seventeen patients were given Isoprinosine (3 g/day) and fifteen were on placebo. The treatment has been lasted for four months, when patients examined monthly. Clinical signs, liver function tests and side effects were evaluated. At the end of the trial, side effects and elevated serum alanine aminotransferase (ALT/GPT) levels occurred with higher frequency in Isoprinosine-treated patients. The results show that this antiviral drug has no beneficial effect in chronic C hepatitis.

Adult↗
PubMed1992

[Clinical and histological findings in HCV-caused hepatitis].

58 cases of acute HCV-hepatitis were studied from the debut of acute illness and were followed up over 1-12 years. A mean three week's delay of anti-HCV IgG (Ortho) positivity was observed after the first manifestation of hepatitis. 70.6% relapsed and a chronic hepatitis developed in 37.9%. Seven patients died in HCV-hepatitis. Clinical, chemical, morphological features of HCV-hepatitis different from other viral hepatitis are demonstrated. Persistence of morphological signs of lobular hepatitis after even several months of subacute and chronic outcome has been found characteristic in HCV-hepatitis. Difficulties in interpretation of liver morphology are discussed. Simultaneous evaluation of clinical picture, laboratory markers and morphology is necessary to select cases for therapeutic trials.

Acute Disease↗
PubMed1992

[Delta virus infection in hemodialyzed kidney patients and patients with chronic liver diseases].

Sera of patients with chronic hepatitis and chronic haemodialysed uraemia were tested for both Hepatitis B virus and Hepatitis Delta virus markers from 1985. Hepatitis Delta virus seroconversion was found in 10 of 88 haemodialysed patients and anti-Delta-IgG sero-positivity in 11 of 108 chronic hepatitis patients. The clinical course of Delta superinfections in haemodialysed patients was as follows: 3 infections were symptomless, 7 patients had acute hepatitis, two of the latter group died because of fulminant hepatitis. Of the 11 HBsAg and anti-Delta-IgG positive chronic hepatitis patients 3 had primary hepatocellular cancer.

Carcinoma, Hepatocellular↗
PubMed1992

[Diagnostic value of the determination of serum alpha2-HS-glycoprotein].

Opsonic glycoprotein, alpha 2-HS-glycoprotein concentration was studied in the serum of 753 patients with various hematological, malignant, immunological, metabolic, endocrine and liver diseases and 68 healthy controls. Decreased serum alpha 2-HS-glycoprotein levels were detected in patients with acute leukemias, chronic granulocyte and myelomonocyte leukemias, lymphomas, myelofibrosis, multiple myeloma, metastatizing solid tumors, systemic lupus erythematosus, rheumatoid arthritis, acute alcoholic hepatitis, fatty liver, chronic active hepatitis, liver cirrhosis, acute and chronic pancreatitis, and Crohn's disease. Elevated levels were measured in patients with B and NANB/C hepatitis. Further decreased levels were observed in some groups with secondary infections. Serum alpha 2-HS-glycoprotein levels are affected by many factors, influencing the synthesis and elimination of the protein. The detection of serum alpha 2-HS-glycoprotein concentration has no specific diagnostic value as a marker for tumors or other diseases, however, its determination can be useful for the assessment of a non-specific regulator of the host defence.

Blood Proteins↗
PubMed1990

[Diagnostic and therapeutic experiences with purulent meningitis in adults].

The authors reviewed data of 137 patients with purulent meningitis treated in the period of 10 years. Attention was paid to the frequency of predisposing and associated diseases, to the factors helping and delaying the diagnosis and to those altering the prognosis. The importance of effective supportive care, particulary covering pressure of the CNS as well as specific therapy was stressed. The circumstances and the conditions of management depending on the condition of the patient was emphasized. Thirty eight of patients (27%) has died.

Adult↗
PubMed1975

Leukocyte migration inhibition by a specific antigen in human brucellosis.

Leukocyte migration inhibition /LMI/ tests were carried out in 19 patients with Brucella abortus bovis infection and in 18 healthy control subjects using killed Brucella abortus bovis as antigen. In the brucellosis group a statistically significant LMI was observed, as compared to the members of the control group. Using the same antigen, a fairly good correlation was found between the local skin reaction and the results of the LMI test in the subacute or chronic stage of the disease. However, the results of the LMI test showed no correlation with either the clinical activity of the disease or the serological results and the general reactions elicited by the skin test. Since LMI and skin tests give nearly identical results in subacute or chronic brucellosis, it is suggested that the LMI test may be used as a safe test instead of the skin test.

Antigens, Bacterial↗